However, some actionable targets can be present in other genes (notably MET, RET, NTRK, and HER2), allowing inclusion into clinical trials of patients with EGFR, ALK, ROS1, and BRAF wild-type tumors with less than 50% PD-L1-positive tumor cells. This evidence concerns the gene RET and neoplasm.